KURA vs. SUPN, TARO, SYRE, RCUS, EWTX, LGND, GPCR, SDGR, HRMY, and AVDL
Should you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Supernus Pharmaceuticals (SUPN), Taro Pharmaceutical Industries (TARO), Spyre Therapeutics (SYRE), Arcus Biosciences (RCUS), Edgewise Therapeutics (EWTX), Ligand Pharmaceuticals (LGND), Structure Therapeutics (GPCR), Schrödinger (SDGR), Harmony Biosciences (HRMY), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical preparations" industry.
Kura Oncology (NASDAQ:KURA) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.
Kura Oncology has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -2.60%. Supernus Pharmaceuticals' return on equity of -1.68% beat Kura Oncology's return on equity.
Supernus Pharmaceuticals received 68 more outperform votes than Kura Oncology when rated by MarketBeat users. Likewise, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 69.01% of users gave Kura Oncology an outperform vote.
Kura Oncology currently has a consensus price target of $27.94, indicating a potential upside of 26.01%. Supernus Pharmaceuticals has a consensus price target of $41.00, indicating a potential upside of 40.89%. Given Supernus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Kura Oncology.
Supernus Pharmaceuticals has higher revenue and earnings than Kura Oncology. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kura Oncology had 11 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 13 mentions for Kura Oncology and 2 mentions for Supernus Pharmaceuticals. Kura Oncology's average media sentiment score of 0.40 beat Supernus Pharmaceuticals' score of 0.34 indicating that Kura Oncology is being referred to more favorably in the media.
Kura Oncology has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.
Summary
Supernus Pharmaceuticals beats Kura Oncology on 10 of the 15 factors compared between the two stocks.
Get Kura Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kura Oncology Competitors List
Related Companies and Tools
